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A B S T R A C T
Currently available hypolipidemic treatments aim at reducing low density lipoprotein 
(LDL)-cholesterol. Unfortunately, cardiovascular events continue to occur despite 
LDL-lowering therapy with use of statins. Recent evidence has revealed that having 
increased concentrations of small LDL particles, though common, is an unhealthy pat-
tern; high concentrations of small LDL particles correlate with much faster growth of 
atheroma, progression of atherosclerosis and earlier and more severe cardiovascular 
events and death. In addition, at any given level of total cholesterol, the relative risk 
of coronary artery disease increases with decreasing levels of high density lipoprotein 
(HDL)-cholesterol. Thus, the target for new interventions would be to reduce small 
LDL particles and increase HDL and/or its apolipoproteins, which are recognized to 
have major vascular protective effects ranging from prevention to stabilization and 
regression of atherosclerosis.
L D L  C H O L E S T E R O L  A N D  L D L  P A R T I C L E S
Atherosclerotic cardiovascular disease is the worldwide leading cause of death, 
which involves multiple pathways in which lipoprotein entry and retention, injury to the 
vessel wall from several stimuli, and inflammation seem to play a key role. Currently 
available treatments are aimed at reducing the high plasma lipid concentrations, most 
particularly low density lipoprotein (LDL)-cholesterol. Increasing evidence has re-
vealed that the concentration and size of the LDL particles are powerfully related to the 
degree of atherosclerosis progression than the concentration of cholesterol contained 
within all the LDL particles.1-3 The LDL particles actually vary in size and density, and 
studies have shown that a pattern that has more small dense LDL particles—called 
“Pattern B”—equates to a higher risk factor for coronary heart disease (CHD) than 
does a pattern with more of the larger and less dense LDL particles (“Pattern A”). 
This is because the smaller particles are more easily able to penetrate the endothe-
lium. “Pattern I,” meaning “intermediate,” indicates that most LDL particles are very 
close in size to the normal gaps in the endothelium (26 nm). The healthiest pattern, 
though relatively rare, is to have small numbers of large LDL particles and no small 
particles. Having small LDL particles, though common, is an unhealthy pattern; high 
concentrations of small LDL particles (even though potentially carrying the same total 
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cholesterol content as a low concentration of large particles) 
correlates with much faster growth of atheroma, progression 
of atherosclerosis and earlier and more severe cardiovascular 
disease events and death.
H D L  C H O L E S T E R O L
Statin therapy has improved event-free survival by lower-
ing LDL-cholesterol and controlling inflammation. Unfor-
tunately, cardiovascular events continue to occur despite 
LDL-lowering therapy. This is probably due to the fact that 
there are risk factors that are important in certain patients 
other than LDL-cholesterol. Therefore, there is a clear need 
for additional preventive and therapeutic interventions to 
complement the results of LDL lowering. Among others 
increased level of high density lipoprotein-cholesterol (HDL-
cholesterol)4,5 is thought to protect against atherosclerosis 
by promoting the efflux of excess cholesterol from cells and 
returning that cholesterol to the liver for secretion into the 
bile, but depends on the repeated transfer of cholesteryl 
esters among lipoproteins before finally the excretion oc-
curs through the liver. Interestingly, during the last several 
years investigators have explored the effect of inflammatory 
stimuli on the formation of a phenotype of HDL with reduced 
anti-atherogenicity, suggesting a link between inflammation 
and HDL functionality. One such target for new interven-
tions is HDL4-6 and/or its apolipoproteins. HDL and/or its 
apolipoproteins have been recognized to have major vascular 
protective effects ranging from prevention to stabilization and 
regression of atherosclerosis. The relationship between low 
levels of HDL-cholesterol and the development of coronary 
heart disease can be inferred from epidemiological studies, 
where even small differences in the level of HDL-cholesterol 
are associated with substantial variations in the risk of major 
coronary events. Data from the Framingham population7 
indicated that at any given level of total cholesterol, the rela-
tive risk of coronary artery disease increases with decreasing 
levels of HDL-cholesterol. Low HDL-cholesterol is commonly 
found in the general population. For example, 18% of men 
and 4% of women in the Framingham Offspring study8 had 
HDL-cholesterol equal or below 35 mg/dl.
The Veterans Affairs cooperative studies program High 
density Intervention Trial (VA-HIT)9 assessed the effect of 
raising HDL-cholesterol levels on CHD-risk in patients with 
low levels of both LDL-cholesterol and HDL-cholesterol. 
After 1-year with gemfibrozil treatment there was a significant 
effect on HDL-cholesterol and total cholesterol but not LDL-
cholesterol, which was associated with a reduction of 22 % in 
non-fatal myocardial infarction or death due to coronary heart 
disease, compared to placebo therapy. For every 5 mg increase 
in HDL-cholesterol, there was a decrease in CHD-death or 
myocardial infarction by 11 %. Furthermore, the PROCAM10 
and the Helsinki Heart studies11 suggest that a high ratio of 
triglyceridemia/HDL cholesterol constitutes a powerful risk 
factor for fatal or non-fatal myocardial infarction that would 
escape attention if LDL cholesterol levels alone were deter-
mined. Dietary and exercise modifications can lead to im-
provement in HDL-cholesterol concentrations, which may be 
associated with greater anti-oxidative role of HDL-cholesterol. 
Kesteloot et al,12 in a Belgian population group, investigated 
the relationship between dietary fat intake and serum total 
and HDL-cholesterol and revealed that polyunsaturated fat 
and the polyunsaturated/saturated fat ratio decrease the 
HDL-cholesterol value, while dietary cholesterol increased the 
HDL-cholesterol level in women only, alcohol consumption 
increased and cigarette smoking decreased HDL-cholesterol 
levels, demonstrating the importance of dietary fat as a de-
terminant of the serum lipid level within a population. The 
key lifestyle changes to increase HDL-cholesterol are weight 
loss in the case of obesity, increased physical activity, smoking 
cessation and alcohol consumption in moderate amounts. With 
smoking cessation for example, HDL-cholesterol increases on 
average 6–8 mg/dl.
D R U G  I N T E R V E N T I O N
Ezetimibe13 is a new selective cholesterol absorption 
inhibitor that blocks the uptake of dietary and biliary choles-
terol by preventing its transport through the intestinal wall, 
without affecting the passage of other fat-soluble nutrients. 
Ezetimibe can reduce LDL-cholesterol levels by up to 19% 
and moderately increases HDL-cholesterol by 3.5%, while it is 
well tolerated when administered with a statin or fibrate with 
additive effects. A combination of simvastatin plus extended 
release niacin,14 currently in clinical development, has been 
demonstrated to produce greater effects on LDL-cholesterol, 
HDL-cholesterol and triglyceride levels than either of the two 
drugs alone; HDL-cholesterol levels were increased by 30 
%, LDL-cholesterol decreased by 47%. However, cutaneous 
flushing resulted in the withdrawal of 7% of patients from 
the study. Another very interesting therapeutic approach is 
the infusion of apolipoprotein A-I,15 the main apolipoprotein 
of HDL. This approach seems to lead also to an increase of 
reverse cholesterol transport and regression of atherosclerosis 
in animal models.
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